Dec 26, 2018
Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
Nov 06, 2018
Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications
Oct 30, 2018
Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties
Oct 25, 2018
Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology
Oct 22, 2018
Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress
Oct 10, 2018
Halozyme To Host Third Quarter 2018 Financial Results Conference Call
Oct 04, 2018
Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment
Sep 20, 2018
Halozyme Therapeutics To Participate In Upcoming Investor Conference
Sep 17, 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin®) In Canada
Aug 22, 2018
Halozyme Therapeutics To Participate In Upcoming Investor Conferences
Jun 11, 2018
Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego
May 29, 2018
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
Mar 14, 2018
Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference
Jan 09, 2018
Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018
Nov 07, 2017
Halozyme Reports Third Quarter 2017 Results
Oct 31, 2017
Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme's ENHANZE Technology
Sep 14, 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Aug 23, 2017
Subcutaneous Immunoglobulin Market to Reach US$8.8 Billion by 2024: Driven by Rising Prevalence of Primary Immunodeficiency Diseases, Market to Exhibit Strong Growth | TMR
Jun 22, 2017
FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology